<DOC>
	<DOCNO>NCT00951834</DOCNO>
	<brief_summary>EGCG show neuroprotective effect cell-experimental animal study . The neuroprotective mechanism EGCG probably base - besides know antioxidant effect - amongst others modulation several signal transduction pathway , influence expression gene regulate cell survival resp . program cell death , well modulation mitochondrial function . In different Alzheimer model EGCG seem cause induction alpha-secretase endothelin-converting-enzyme , well prevent aggregation beta-amyloid toxic oligomers direct bind unfolded peptide . The investigator therefore expect EGCG positive influence course Alzheimer´s Disease .</brief_summary>
	<brief_title>Sunphenon EGCg ( Epigallocatechin-Gallate ) Early Stage Alzheimer´s Disease</brief_title>
	<detailed_description>Alzheimer 's disease ( AD ) progressive dementia characterise ongoing loss memory function least one additional cognitive domain result impairment daily life functioning . Treatment diseases diabetes mellitus , fracture cardiovascular disease expensive complicate patient dementia compare without . The yearly cost treatment care AD patient US estimate exceed 100 billion USD . Life expectancy report 10 year establishment diagnosis significantly reduce compare non-demented subject similar age socio-economic status . Age relevant risk factor AD , follow genetic factor . Prevalence le 1 % amongst individual age 50-60 , report double every 5 year beyond age 60 . The prevalence exceed 30 % age 85-90 . The standard therapy AD acetylcholine-esterase inhibitor ( AchEI ; donepezil , galantamine , rivastigmine ) . AchEI exhibit temporary stabilizing mild effect progression AD . Conversion rate `` mild cognitive impairment '' AD seem beneficially influence AchEI . A high percentage premature study withdrawal owe adverse event observe AchEI study publish date . The questionable benefit may outweigh high cost AchEI . Therefore , necessity development efficacious less expensive disease-modifying drug well safety tolerability profile . EGCG promise compound proven efficacious AD animal model show excellent tolerability 18-month clinical trial Multiple Sclerosis currently perform institution ( SuniMS study , NCT00525668 ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>early stage AD ( Diagnosis DSMIV NINCDS/ADRDA , Duboiscriteria 2007 ) age 60100 MMSE 2026 patient live home least one relative perform external ratings/assessment comedication Donepezil ( Aricept® , Pfizer Pharma GmbH ) least 3 month maximum 6 month exist stable medication maximum 2 cup black tea/die , green tea , &gt; 500 ml/die grapefruit juice comedication NSAIDs ( longterm medication ) ( ASS exclusion criterion ) , Gingko natural extract , antidementiva except Donepezil familial autosomaldominant inherit AD instable medical condition primary psychiatric/neurologic disorder miss informed consent readiness save refer pseudonym personal data hospitalisation due juridical legal regulation condition disturb make MRI measure impossible clinically relevant GIdisorders screen 1 year clinically relevant lung , infectious , heart CNS disorder , clinical paraclinical suspicion TBC , history vascular CNSdisorders screen 1 year clinically relevant liver disorder screen 1 year clinically relevant functional disorder liver , kidney bone marrow define follow lab value screen : Marrow dysfunction : HB &lt; 8,5 g/dl WBC &lt; 2,5/nl Thrombocytes &lt; 125/nl Kidney dysfunction : CreatininClearance accord CockcroftGaultFormula : Cl &lt; 110ml/min ( male ) resp . Cl &lt; 95ml/min ( female ) , age 30 decline 10ml/min per decade Liver dysfunction : ASAT/ALAT &gt; 3.5 x high upper reference value Bilirubin &gt; 2.0 mg/dl know allergy element Sunphenon EGCg additives Sunphenon EGCg resp . placebo longterm hepatotoxic medication current intake cytochrom P450 3A4inhibitors inductor , antimycotic azoltype macrolideantibiotics clinicalanamnestic paraclinical manifestation suggest alcohol drug abuse participation clinical trial &lt; 3 month prior screen ongoing medical , psychiatric condition might constrain ability patient understand inform consent , give consent , adhere protocol accomplish study massive extend sun exposure</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Alzheimer´s Disease</keyword>
	<keyword>Epigallocatechin-Gallate</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>ADAS-COG</keyword>
	<keyword>early stage Alzheimer 's Disease</keyword>
</DOC>